At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 160 enrolled
Drug / intervention
PRO-155 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Randomized, Double-blind Clinical Trial to Evaluate Efficacy and Safety of the Ophthalmic Solution PRO-155 Versus Nevanac 0.1% Ophthalmic Solution in Post Phacoemulsification Patients
In Brief
A Phase 2 clinical trial evaluating PRO-155 and Nevanac for Cataract and Phacoemulsification Cataract Surgery. Completed, enrolled 160 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate efficacy and safety of the ophthalmic solution PRO-155 in patients post phacoemulsification.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract, Phacoemulsification Cataract Surgery
CountriesMexico
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartDec 2013
Primary CompletionMar 2015
Study CompletionApr 2015
TodayJul 2026
First PostedAug 6, 2012
Enrollment StartDec 1, 2013
Primary CompletionMar 1, 2015
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.9 years ago
Interventions
PRO-155drug
Pre-medication (before surgery) and maintenance treatment.
Nevanacdrug
Pre-medication (before surgery) and maintenance treatment.